Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain

More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.

More from Pricing Debate

More from Market Access